Binding Site Expands Product Line To Include Myeloperoxidase - pANCA Antigen -- MEDICA - World Forum for Medicine


The Binding Site GmbH

Binding Site Expands Product Line To Include Myeloperoxidase - pANCA Antigen

MPO Photo Graphic
The Binding Site Inc. has formally announced the addition of the Arotec Diagnostics’ Myeloperoxidase-pANCA antigen to its already broad offering of clinical and research products and services. Antibodies to Myeloperoxidase have been observed in patients with various types of systemic vasculitis, idiopathic crescentic glomerulonephritis, Churg-Strauss syndrome, microscopic polyangiitis, polyarteritis nodosa, rheumatoid arthritis (RA) and inflammatory bowel disease. Elevated plasma levels have also been reported and seen in acute coronary syndromes and with some malignancies. As such, the availability of this product will serve to benefit the needs of clinical researchers, laboratory professionals and in-vitro diagnostic (IVD) manufacturers, as it has been expressly designed for use as an integral component in solid phase ELISA-based immunoassay test procedures.
Derived and sourced from human neutrophils and tested to be free of HBs-Ag, HCV, HIV-1 & HIV-2, this Myeloperoxidase antigen exhibits a purity level greater than 95%, as assessed by SDS gel electrophoresis. It also displays the highest degrees of activity and specificity, while demonstrating exceptional shelf life stability and lot-to-lot consistency. The Myeloperoxidase antigen is available in a range variety of packaging formats, including 1.0 mg; 0.5 mg and 0.2 mg standard fill vials. Bulk packaging configurations are also available.
The Binding Site, Inc. serves the in-vitro diagnostic and life science markets with a comprehensive line of innovative products. For additional information, contact The Binding Site, Inc. at 5889 Oberlin Drive – Suite 101, San Diego, CA 92121 USA. Phone: 800-633-4484; FAX: 858-453-9189; Email: Please visit our website at